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Abstract Atrial fibrillation (AF) is the most prevalent
cardiac arrhythmia with a strong genetic component.
Molecular pathways involving the homeodomain tran-
scription factor Shox2 control the development and func-
tion of the cardiac conduction system in mouse and
zebrafish. Here we report the analysis of human SHOX2 as
a potential susceptibility gene for early-onset AF. To
identify causal variants and define the underlying mecha-
nisms, results from 378 patients with early-onset AF before
the age of 60 years were analyzed and compared to 1870
controls or reference datasets. We identified two missense
mutations (p.G81E, p.H283Q), that were predicted as
damaging. Transactivation studies using SHOX2 targets
and phenotypic rescue experiments in zebrafish demon-
strated that the p.H283Q mutation severely affects SHOX2
pacemaker function. We also demonstrate an association
between a 30UTR variant c.*28T[C of SHOX2 and AF
(p = 0.00515). Patients carrying this variant present sig-
nificantly longer PR intervals. Mechanistically, this variant
creates a functional binding site for hsa-miR-92b-5p. Cir-
culating hsa-miR-92b-5p plasma levels were significantly
altered in AF patients carrying the 30UTR variant
(p = 0.0095). Finally, we demonstrate significantly
reduced SHOX2 expression levels in right atrial appen-
dages of AF patients compared to patients with sinus
rhythm. Together, these results suggest a genetic contri-
bution of SHOX2 in early-onset AF.
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Introduction
Developing approaches towards disease prediction and
treatment of heart rhythm disorders is an important topic in
healthy aging. Atrial fibrillation (AF) is the most common
cardiac rhythm disturbance affecting 1–2 % of the general
population [34]. Disorganized electrical activity of the atria
results in irregular and often rapid heart rates. Prevalence
of AF generally increases with advancing age and the
presence of concomitant cardiovascular diseases [34].
Many important aspects of AF pathophysiology have been
described [4, 23], and various studies have demonstrated
that the genetic background plays a significant role in its
pathogenesis [14, 43, 46].
In 2003, Chen et al. published the first report on a
mutation in the potassium channel gene KCNQ1 co-seg-
regating with AF in a single family [9]. Since then,
mutations have been identified in various genes encoding
ion channels, cardiac gap junctions and signaling mole-
cules. These defective proteins have been shown to con-
tribute to abnormal electrical properties, thereby leading to
increased susceptibility of inherited AF [37]. Transcription
factors have been recently emerged as important contrib-
utors to AF susceptibility [36]. In addition to rare mutations
in transcription factor genes with a strong phenotype
(GATA4/5/6, NKX2.5, TBX5), common variants located in
or close to transcription factor genes (PITX2, ZFHX3,
PRRX1, MEIS1, NKX2.5, TBX5) have been identified to be
associated with AF by genome wide association studies
(GWAS) [16, 18, 22, 25, 39, 46]. Genetic variants upstream
of the PITX2 gene (4q25 risk locus) for example, show the
strongest association with AF [22, 28], but the SNPs in this
region have not been directly linked to expression levels of
PITX2 in patients. Nonetheless, our current understanding
of PITX2 function strongly suggests a functional link
between this gene and AF. Pitx2 haploinsufficiency in adult
mice results in an increased susceptibility to AF after
electrical stimulation [30, 49]. Additional approaches have
demonstrated that Pitx2 constitutes a repressor of Shox2
and thereby inhibits the specification of a left-sided pace-
maker, preventing predisposition to AF [49]. More recently
it has been shown that a genetic pathway, including Pitx2,
miR-17-92 and miR-106b-25 directly repress SAN regula-
tory genes such as Shox2, which delimits SAN develop-
ment and inhibits AF susceptibility [48]. Similarly, the
T-box transcription factor TBX5 which is causative for
Holt-Oram syndrome and which in some cases associates
with AF, has also been shown to represent an upstream
regulator of SHOX2 [40].
The homeodomain transcription factor Shox2 has vari-
ous and distinct developmental functions, especially in the
development of the sinoatrial node (SAN) region, the
primary pacemaker [6, 7, 19, 52]. A knockout mouse
model verified this key role for Shox2 in SAN development
and specification during early cardiac formation [6, 19].
Homozygous Shox2-/- embryos die between E11.5 and
E17.5 due to cardiovascular defects [6]. This pivotal role in
pacemaker function was further demonstrated by the severe
bradycardia after knockdown of Shox2 in zebrafish
embryos and markedly reduced heart rates in isolated
murine Shox2-/- hearts [6, 19, 24, 32, 40]. Furthermore, it
has also been demonstrated that a Shox2 dependent genetic
program primes the pacemaker cells in the pulmonary vein
myocardium, a vulnerable substrate for ectopic electrical
activity initiating AF [53].
Several clinical studies as well as animal experiments
have demonstrated a link between sinus node dysfunction
and atrial fibrillation; SAN electrical activity, for example,
has been demonstrated to modulate pulmonary vein
arrhythmogenesis as a trigger of AF [8]. Nonetheless, it is
not yet clear whether AF develops as a result of SAN
dysfunction or vice versa, or if both share a common
pathophysiological mechanism.
In this study, we investigate SHOX2 as a potential sus-
ceptibility gene for atrial fibrillation in a large set of
patients with early-onset AF. To identify causal variants
and the underlying mechanisms by which they act, we
included all coding exons but also parts of the 50 and 30
untranslated regions (UTRs) of the SHOX2 gene. To elu-
cidate the molecular mechanisms, functional in vitro and
in vivo studies were carried out.
Results
Mutation analysis of the SHOX2 gene in patients
with atrial fibrillation
To investigate a possible role of SHOX2 in atrial fibrillation
(AF), we performed a mutational screen in 378 patients
with early-onset AF before the age of 60 years
(14–60 years). Clinical characteristics of the study cohort
are listed in Table S1. Sequencing all coding exons as well
as parts of the 50 and 30UTRs of the SHOX2 gene identified
a variant in the 30UTR (c.*28T[C; rs138912749) and two
missense mutations (c.242G[A, c.849C[A) (Fig. 1A, B).
The c.*28T[C 30UTR variant was identified in 15
unrelated individuals. To address the significance of the
30UTR variant, it was genotyped in a control cohort.
Selecting appropriate controls is a particular challenge in
case–control association studies. We selected a specific
control group with a certain guarantee neither to suffer nor
to develop arrhythmias. This group comprised 1576 unre-
lated long-lived individuals with an age of 95–109 years
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from the German longevity collection [38]. A second
control group matched the patient population in terms of
age (25–70 years). Genotyping of a total of 378 unrelated
AF patients versus 1576 long-lived controls as well as 294
younger healthy individuals demonstrated a significant
association between the SHOX2 30UTR variant and AF
(p = 0.00515, OR = 2.373) (Fig. 2). Note that both con-
trol groups show similar minor allele frequencies (MAF) of
0.9 and 0.7 %, respectively.
The identified missense mutations are both unique and
have been detected each in a single patient. The c.242G[A
exchange causes an amino acid substitution of glycine to
glutamic acid (p.G81E). The c.849C[Amutation results in a
substitution of histidine to glutamine (p.H283Q) (Fig. 1B,
C). Both amino acids reside at evolutionary conserved sites
with p.G81 being conserved among mammals and p.H283
highly conserved among vertebrates (Fig. 1C). Different in
silico analyses (PolyPhen2, Mutation Taster, PROVEAN,
Hansa) predicted that the p.H283Q missense mutation is
disease causing (deleterious), while p.G81E is predicted as
possibly damaging. Both SHOX2 amino acid variants were
absent in the 1000 Genomes dataset (http://www.1000gen
omes.org/) and the Exome Variant Server (http://evs.gs.
washingon.edu/EVS/). Thus, both mutations were consid-
ered as disease causing and further investigated.
Functional characterization of the SHOX2 30UTR
variant
To functionally characterize the 30UTR variant exhaustive
search for 6-mer seed matches (i.e. perfect complement to
miRNA nt 2-7) to the known human miRNAs (as in
miRBase v20; http://www.mirbase.org/) was carried out
and revealed that the c.*28T[C variant in the 30UTR cre-
ates a putative 8 base binding site for hsa-miR-92b-5p in
the SHOX2 gene (Fig. 3A). Co-expression of mRNA and
miRNA is a key requirement for a regulatory mechanism.
Expression of hsa-miR-92b-5p was therefore first tested in
various fetal and adult human tissues including heart
(Fig. S1). Comparative expression analysis of SHOX2 and
miR-92b-5p was then carried out in human fetal and adult
heart, mouse E11.5 right atrium (containing the SAN
region) and total heart, and murine HL-1 cells. Both,
mRNA and miRNA are co-expressed in these tissues
(Fig. 3B). SHOX2 expression has also been previously
demonstrated in the SAN of human embryos (7 weeks
post-conception), implicating a similar role of human and
mouse SHOX2 in SAN development [31].
To assess the functional relevance of the novel miR-92b-
5p binding site, we carried out luciferase reporter assays.
Reporter constructs containing the full-length wild type
(c.*28T) or mutant (c.*28C) SHOX2 30UTRs were gener-
ated. Transient co-transfection of HEK293 cells and atrial
cardiomyocytes (HL-1 cells) with wild type or mutant
reporter constructs together with miR-92b-5p or negative
control miRNA revealed significantly reduced luciferase
activity of the mutant. Both cell lines revealed similar
results, HEK293: p = 0.0070; HL-1: p = 0.0052
(Fig. 3C). Comparable results were obtained using a sec-
ond luciferase reporter vector (pRL-TK) containing only
part of the SHOX2 30UTR (Fig. S2). To confirm the
specificity of miR-92b-5p on luciferase activity of the
mutant SHOX2 30UTR reporter, we repeated the assays
using a specific miR-92b-5p or negative control inhibitor.
While the allele-specific effect of miR-92b-5p was com-
pletely reversed by the miR-92b-5p inhibitor, it was not
altered using a control inhibitor (Fig. 3D). Together, these
results show that miR-92b-5p is capable of targeting the
SHOX2 30UTR carrying the c.*28C variant.
Interestingly, subsequent detailed clinical data analysis
of patients carrying the 30UTR variant (T/C genotype)
revealed a significantly prolonged PR interval over 200 ms
reflecting prolonged atrial and atrioventricular node con-
duction (Fig. 4Aa, Table S1) and indicating alterations of
either the sinoatrial, atrial, or atrioventricular nodal elec-
trical properties. No differences were seen for other elec-
trocardiographic (ECG) parameters (RR interval, QRS
duration, QT interval) or any clinical characteristics (age at
onset, type of AF, family history, concomitant diseases,
risk factors, or echocardiographic parameters) comparing
AF patients carrying the variant (T/C) to patients with the
T/T genotype (Fig. 4Ab-d, Table S1).
As changes in circulating miRNA levels often reflect an
altered physiological state of an organ or tissue [13], we
investigated the expression of miR-92b-5p in the plasma of
AF patients versus healthy controls. No significant differ-
ences were detected (Fig. 4Ba). Clinical characteristics of
patients where plasma samples were available are listed in
Table S2. When we, however, split the patient cohort in
T/T (n = 17) and T/C (n = 6) genotype carriers, patients
with the T/C genotype had significantly decreased hsa-
miR-92b-5p plasma levels (p = 0.0129) compared to AF
patients with T/T genotype (Fig. 4Bb). When we further
split the AF patients with T/T genotype into two groups
according to their PR interval length (\200 ms,
n = 8;[200 ms, n = 9) and compare them with T/C
genotype carriers with prolonged PR intervals (n = 6), the
effect is even more pronounced (p = 0.0095) (Fig. 4Bc).
These findings point to hsa-miR-92b-5p as a putative
regulator of SHOX2 expression in a distinct subgroup of
AF patients.
Functional relevance of SHOX2 missense mutations
To investigate the functional significance of the two mis-
sense mutations, subcellular localization of the SHOX2
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mutants was determined in HEK293 and HL-1 cells and
compared to wild type. Consistent with its role as tran-
scription factor, wild type as well as p.G81E or p.H283Q
SHOX2 mutants localized to the nucleus (data not shown).
Next, we performed luciferase reporter assays to determine
whether the identified mutations have an impact on the
transactivational activity of SHOX2. Wild type SHOX2
activates the promoter of its previously described target
genes BMP4 and ISL1 [24, 40]. We could show that
SHOX2 harboring the p.G81E mutation has still transac-
tivational activity similar to wild type, while the p.H283Q
mutant severely affects the transactivational activity and
was not able to activate its targets (Fig. 5A).
Functional in vivo characterization was carried out in
zebrafish for the p.H283Q mutation, which affects an
evolutionary highly conserved amino acid (the p.G81E
mutant was not conserved in zebrafish). DNA constructs
expressing wild type and mutant shox2 under the control of
the cardiac myosin light chain 2 (cmlc2) promoter [26],
driving myocardial-specific expression, were used in
overexpression experiments (zebrafish Shox2 p.H227Q
corresponds to human SHOX2 p.H283Q). The cmlc2 pro-
moter also drives expression of GFP, allowing the moni-
toring of cardiomyocyte-specific expression. The mean
heart rate of control embryos 72 h post fertilization (hpf)
amounts to 150 beats per minute (bpm).
Injection of the shox2 mutant p.H227Q expression
construct into wild type zebrafish embryos at the one-cell
stage did not cause any changes in embryonic heart rate
(151 bpm) at 72 hpf, implying that the Shox2 p.H227Q
mutant does not act in a dominant-negative manner in
zebrafish in vivo.
As shown previously, targeted knockdown of zebrafish
Shox2 using Morpholino-modified antisense oligonu-
cleotides (MO) leads to pericardial edema and pericardial
blood congestion due to severely reduced heart rates in
zebrafish embryos [24]. We also demonstrated that brady-
cardia in Shox2 morphants can be rescued by cardiomy-
ocyte-specific expression of wild type Shox2 [24]. Here,
we used this approach to address whether the Shox2 mutant
is also able to rescue the Shox2 morphant phenotype or
whether the p.H227Q mutation leads to a loss of Shox2
function. First we co-injected 0.32 ng of the respective
expression construct along with 2.8 ng shox2 MO, suffi-
cient to induce the known bradycardia phenotype [24] and
then monitored visible morphological changes and heart
rate of GFP positive embryos after 72 hpf. While
myocardial-specific expression of wild type Shox2 could
rescue the pericardial edema and reduced heart rate in
Shox2 morphant embryos (137 vs. 87 bpm; p =\0.0001),
this was not the case for the p.H227Q mutant (96 vs.
87 bpm) (Fig. 5B, C). These data indicate that the zebrafish
p.H227Q mutation (corresponding to human p.H283Q)
bFig. 1 Identified SHOX2 variants in patients with atrial fibrillation.
A Schematic drawing showing the position of the identified coding
and non-coding variants within the SHOX2 gene. The SHOX2a
isoform is composed of 7 exons. All exons are highly conserved
between species except exon II? which is restricted to primates.
B Electropherograms showing the substitutions detected in the
SHOX2 gene in patients with atrial fibrillation and their respective
wild type counterparts. C Multiple sequence alignment of SHOX2
protein and 30UTR parts among different species. The amino acid
p.G81 encoded within exon 1 is conserved among mammals (a). The
amino acid p.H283 encoded within exon 6 is highly evolutionary
conserved across vertebrates (b). The SHOX2 30UTR sequence around
the c.*28T[C variant is only present in primates and not conserved
between species (c). The multiple sequence alignment was done using
Clustal Omega for protein sequences and MAFFT program with
Q-INS-i algorithm for 30UTR sequences
Fig. 2 Association analysis of SHOX2 30UTR variant c.*28T[C with
atrial fibrillation. Values indicate number of patients and controls with
the respective genotype (T/T = wild type; T/C = variant). Odds ratio
(OR), 95 % confidence interval (CI) and p-value were calculated
using the Chi squared (v2) test. The control cohort consists of 294
unrelated healthy individuals and 1576 long-lived individuals from
the German longevity collection [38]
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leads to a loss of regular Shox2 function and thereby
impairs cardiac pacemaker function in vivo.
SHOX2 expression in right atrial appendages of AF
patients
To investigate SHOX2 expression levels in human tissue
specimens, right atrial appendages were obtained during
cardiac surgery from patients with AF and patients with
sinus rhythm (n = 17 for each group). Expression analysis
revealed significantly reduced SHOX2 transcripts in AF
patients compared to the control group (p = 0.0226;
Fig. 6A). Next, we examined ECG recordings from these
patients and found significantly longer PR intervals
(p = 0.0157) in AF patients compared to patients with
sinus rhythm (Fig. 6B), whereas other ECG parameters
(RR interval, QRS duration, QT interval) were unchanged
(data not shown).
Together, our data demonstrate for the first time coding
and non-coding variants in SHOX2 in patients with atrial
fibrillation. We also established a link between the
observed genotype to an intermediate AF phenotype with
Fig. 3 Functional characterization of SHOX2 30UTR variant.
A SHOX2 30UTR with the c.*28C allele creates a novel miR-92b-
5p binding site (pairing of the seed region is shown). B SHOX2
mRNA (left) and miR-92b-5p (right) expression levels in human and
murine heart tissues (human fetal and adult heart, mouse embryonic
total heart and right atrium (RA) E11.5) and HL-1 cells (derived from
mouse atrial cardiomyocytes). SHOX2 mRNA and miRNA (miR-92b-
5p) are co-expressed in the same tissues. C Luciferase activity of wild
type (c.*28T) or mutant (c.*28C) psiCHECK2-SHOX2 30UTR
constructs, co-expressed with miR-92b-5p (indicated in light grey)
or negative control miRNA (miR-ctrl, indicated in dark grey) in
HEK293 and HL-1 cells, determined 48 h after transfection. miR-92b-
5p significantly reduces the activity of the mutant but not the wild
type SHOX2 30UTR reporter in both cell lines. D HEK293 cells were
transiently co-transfected with mutant (c.*28C) psiCHECK2-SHOX2
30UTR reporter and miR-92b-5p together with either miR-92b-5p
inhibitor or negative control inhibitor (ctrl-inhibitor) and luciferase
activity was determined after 48 h. The allele-specific effect of miR-
92b-5p on the luciferase activity of the mutant SHOX2 30UTR
reporter is reversed by a specific miR-92b-5p inhibitor, but not altered
using the control inhibitor. Data are expressed as mean ± SEM of
3–4 independent experiments. For each experiment triplicates were
measured. p values were determined by a paired t test (*p\ 0.05;
**p\ 0.01, ns not significant)
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prolonged PR interval inferred from reduced SHOX2
expression levels in this cohort.
Discussion
Genetic causes underlying cardiac arrhythmias are many-
fold and incompletely understood. Gaining more insights
into the mechanistic basis of atrial fibrillation (AF), the
most common arrhythmia, will allow the development of
more effective, personalized diagnostic and therapeutic
approaches. In the last few years, transcription factors, their
targets and transcriptional modifiers have been shown to
play important roles in AF pathophysiology, indicating that
dysregulated gene expression is an essential underlying
mechanism [36].
Previous studies in mouse and zebrafish have suggested
a pivotal role for the transcription factor Shox2 during
cardiac development, especially in the pacemaker region
and sinoatrial node (SAN) function, suggesting SHOX2 as
possible susceptibility gene for cardiac arrhythmias [6, 24,
32, 40]. Our current study provides first convincing evi-
dence for a link between SHOX2 and atrial fibrillation in
humans. Our study cohort comprised 378 AF patients with
an early-onset of disease before the age of 60 years.
Screening this patient cohort, three different heterozygous
Fig. 4 Clinical data analysis of AF patients. A Electrocardiographic
parameters of analyzed AF patients. Patients not carrying the SHOX2
30UTR variant c.*28T[C (dark grey bars, n = 361, T/T genotype)
compared to carriers of the variant (light grey bars, n = 15, T/C
genotype). PR interval (a). RR interval (b). QRS duration (c). QT
interval (d). Data are presented as mean ± SEM. p-values were
determined by an unpaired t test (***p\ 0.001). B MiR-92b-5p
expression in human plasma. Healthy controls (n = 12) compared to
AF patients (n = 23) (a). AF patients with T/T genotype (n = 17)
compared to AF patients with T/C genotype (n = 6) (b). AF patients
with T/C genotype and PR intervals[200 ms (n = 6) compared to
AF patients with T/T genotype and PR intervals[200 ms (n = 9) or
to AF patients with T/T genotype and PR intervals\200 ms (n = 8)
(c). Data are presented as mean ± SEM. p-values were determined by
an unpaired t test (*p\ 0.05; **p\ 0.01)
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sequence variants were identified, including a 30UTR
variant and two novel missense mutations.
The 30UTR variant c.*28T[C was identified in 15/378
patients (MAF 2 %). It was also found to be present in the
general population (MAF 0.7–0.9 %) without known AF. In
the control group comprising 1576 German long-lived
individuals (above 95 years of age), the c.*28T[C variant
was detectedwith aMAFof 0.9 %.Additional genotyping of
294 unrelated healthy German individuals (25–70 years)
revealed aMAF of 0.7 %. Statistical validation of the 30UTR
variant in 378 patients versus the combined control cohorts
(1870 individuals) resulted in a statistical significance of
p = 0.00515. Public databases (1000 Genomes Project),
annotated this variant as a SNP (rs138912749)with aMAFof
0.7 %, comparable to our genotyped control cohorts.
The majority of miRNAs recognize their targets solely
through direct binding to their seed sequence. Regulatory
variants in the 30UTR of genes may therefore create or
disturb miRNA binding sites. So far only a few examples
of regulatory variants have been identified and linked to a
disease or phenotype [1, 3, 12, 29]. We have identified a
SNP in the 3´UTR of SHOX2 that has been shown to create
a novel miRNA target site for miR-92b-5p. MiRNAs rep-
resent important post-transcriptional modifiers of gene
expression by targeting the 30UTR of messenger RNAs and
thereby controlling developmental processes [5, 33]. Col-
lectively, they affect nearly all cellular pathways including
proarrhythmogenic signaling cascades in the heart [41, 47,
50]. Several miRNAs have been demonstrated in the
pathophysiology of AF. Either they are involved in the
control of atrial electrical remodeling by regulating ion
channels, transporters and Ca2?-handling proteins, or have
an impact on atrial structural remodeling by regulating
fibrosis and apoptosis [15, 35, 41]. Both, electrical and
structural remodeling processes of the atria are strongly
associated with AF. Recently, it has also been shown that
Pitx2 upregulates the miR-17-92/106b-25 cluster, that in
turn represses Shox2 resulting in delimited sinoatrial node
development. Deletion of this miRNA cluster in mice
results in sinus node dysfunction, PR prolongation and
predisposition of AF [48]. This study demonstrates that
bFig. 5 Functional characterization of the SHOX2 coding variants.
A Luciferase activity of BMP4 (left) or ISL1 (right) luciferase reporter
constructs co-expressed with SHOX2 wild type (Wt) or SHOX2
mutants (p.G81E; p.H283Q) in HEK293 cells (human embryonic
kidney cells), determined 24 h after transfection. All values are
reported as fold changes of luciferase activity normalized to the
empty vector (pGL3 basic) co-transfected with the respective
expression constructs. Data are expressed as mean ± SEM of four
independent experiments performed in triplicate. p values were
determined by a paired t test (*p\ 0.05; **p\ 0.01; ***p\ 0.001).
B Injection of shox2 antisense morpholino (MO), which leads to
pericardial edema and pericardial blood congestion due to reduced
heart rates in zebrafish can not be rescued by cardiomyocyte-specific
overexpression of shox2 Mut p.H227Q (corresponds to human
SHOX2 p.H283Q mutation) compared to shox2 Wt (wild type)
72 h post fertilization (hpf). C The mean heart rate of control
embryos 72 hpf amounts to 149 beats per minute (bpm). After shox2
knockdown, the heart rate is significantly reduced to 87 bpm. While
cardiomyocyte-specific overexpression of Wt shox2 rescues the MO-
mediated bradycardia (137 bpm), overexpression of shox2 Mut
p.H227Q does not alter the reduced heart rate significantly at 72
hpf (95 bpm). Data are expressed as mean ± SEM of 3 independent
experiments. p values were determined by one-way ANOVA with
Sidak’s multiple comparisons test (****p\ 0.0001; ns not signifi-
cant; n = 10–16 per condition per experiment)
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Shox2 is an important factor regulating the development
and maintenance of the whole cardiac conduction system
rather than exclusively mediating sinus node development.
The two miRNAs,miR-92b-3p and 92b-5p, are processed
from the same precursor molecule, but only the biological
function ofmiR-92b-3p has been investigated so far [10, 54].
Hsa-miR-92b-3p has been implicated in various cardiovas-
cular disorders including coronary artery disease and chronic
systolic heart failure [21, 45]. Here, we provide first evidence
for a functional relevance of miR-92b-5p during heart
development and in the pathogenesis of AF. We demon-
strated that a novel hsa-miR-92b-5p target site generated by a
genetic variant in the 30UTR of the SHOX2 gene may reduce
SHOX2 expression and thereby facilitate proarrythmogenic
remodeling leading toAF. This appears to have a remarkable
effect on circulating hsa-miR-92b-5p plasma levels, which
are decreased by threefold in those patients with the T/C
genotype (n = 6), compared to AF patients with the wild
type allele (n = 8). AlthoughmiRNA levels in plasma could
be investigated only in a limited number of patients so far, a
significant difference was noted.
A deeper understanding of the reciprocal function of
miRNAs and their targets according to their relative
abundance inside the cell is still lacking. As a mechanism
one may argue that altered intracellular miR-92b-5p target
site abundance may result in decreased extracellular levels,
since more miR-92b-5p is used within the tissue. This
option, however, seems unlikely, as for most mRNAs its
contribution to miRNA binding is largely diluted by the
effects of all the other mRNA in the cell [17]. One could
also hypothesize that some targets are known to induce
miRNA degradation leading to decreased extracellular
plasma levels [2] but so far little is known about the
mechanisms or the determinants of this phenomenon.
We have found that the AF patients carrying the SHOX2
30UTR c.*28C allele have significantly prolonged PR
intervals compared to patients with the wild type allele.
Results of the Framingham heart study demonstrated that
prolonged PR intervals increase the risk for AF and predict
a more severe disease progression and worse prognosis
[11]. Furthermore, our finding is in line with the study by
Wang et al. showing that miRNA-mediated alterations of
Shox2 expression in mice also result in PR prolongation
and increased susceptibility to AF [48].
Cardiogenesis is a developmental process tightly con-
trolled by an orchestrated network of transcriptional regu-
lators. Correct dosage is essential, since haploinsufficiency
of a single regulatory factor can shift a fine-tuned balance
and result in severe defects [42]. In the mouse, the
homozygous loss of Shox2 results in embryonic lethality
with bradycardia, whereas heterozygous mice have not yet
been studied in much detail [6, 19]. In a mouse model
where Shox2 was replaced by the closely related but
hypomorphic SHOX allele, embryonic lethality could be
rescued, but arrhythmias remained [31]. These data add
further weight to the findings that haploinsufficient muta-
tions in SHOX2 can trigger arrhythmia phenotypes, sug-
gesting a maintenance role of SHOX2 in the adult heart.
To understand the underlying molecular mechanism by
which the identified missense mutations may act, transac-
tivation studies with the two known direct SHOX2 target
genes BMP4 and ISL1 [40] were carried out. While the
p.G81E mutant did not affect the transactivational activity
of SHOX2, the p.H283Q mutant was unable to activate
both BMP4 and ISL1 target genes. Further functional val-
idation of the p.H238Q mutant was then carried out in
zebrafish. Cardiac electrophysiology in the zebrafish dis-
plays several common features compared to humans. First,
the heart rate of an adult zebrafish (about 120 bpm) is very
similar to the human situation. Excitation is generated in
specialized pacemaker cells at the inflow tract of the atrium
[52] and is rapidly propagated to the ventricle with a
characteristic delay at the atrioventricular canal. Interest-
ingly, cardiac pacemaker cells closely resemble those in
mammals especially in respect to their gene expression
pattern and electrochemical properties [52]. Furthermore,
Fig. 6 SHOX2 expression in right atrial tissue of AF patients.
A SHOX2 mRNA levels are significantly reduced in right atrial
appendages from patients with AF (n = 17) compared to patients
with sinus rhythm and no previous history of AF (n = 17). B PR
intervals (where available) are significantly prolonged in AF subjects
(n = 10) compared to patients with sinus rhythm (n = 15). Data are
presented as mean ± SEM. p values were determined by an unpaired
t test (*p\ 0.05)
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the cellular and molecular mechanisms that underly auto-
maticity, refractoriness and conduction of the heart are
conserved between zebrafish and humans [44, 46].
It was previously demonstrated that MO-mediated
shox2 deficiency in zebrafish leads to pericardial edema
and blood congestion due to severely reduced heart rates
[6, 24]. Using this phenotype as a read out, we injected the
zebrafish p.H227Q mutant (which corresponds to the
human p.H283Q mutation) in a rescue experiment. In
contrast to wild type, the mutant Shox2 was not able to
compensate the Shox2 deficiency and rescue the pheno-
type. These data demonstrate that the missense mutation
H283Q, which affects a highly conserved amino acid,
severely impairs the biological function of SHOX2.
In summary, several studies have demonstrated that
Shox2 is an important regulator of the cardiac conduction
system and that alterations of Shox2 expression can impair
electrical properties of the heart resulting in sinus node
dysfunction, conduction slowing, or arrhythmias [6, 52].
To determine if these experimental findings also hold true
in humans, SHOX2 expression was measured in heart tissue
from patients. Significantly reduced SHOX2 expression
levels were demonstrated in atrial tissue from patients with
AF compared to patients with normal sinus rhythm and no
previous history of AF. These findings are hypothesis-
generating and we propose that reduced SHOX2 expression
caused by coding and regulatory variants in patients con-
tribute to the observed arrhythmic phenotype of AF with
prolonged PR interval.
Developing a mechanistic classification of AF based on
health modifiers like genetic susceptibility is essential to
improve personalized prevention and management of AF
[20]. Our findings contribute to a better classification of
AF, since a specific patient cohort with early-onset AF and
prolonged PR interval could be determined by genetic
predisposition involving the SHOX2 gene.
Our findings have also provided genetic evidence for a
novel miRNA target site contributing to and resulting in
AF predisposition. Replication in other large patient
cohorts will show, whether circulating miR-92b-5p has the
potential to serve as a non-invasive biomarker and
promising therapeutic target in the personalized diagnosis,




The patient cohort comprised 378 German individuals with
atrial fibrillation (AF). Only patients with early-onset AF
were included, i.e. onset of AF before the age of 60 years
(14–60 years). Patients were recruited from 2001 to 2013
in the context of a general biobanking effort. About 80 %
of all eligible patients were recruited; around 55 % of the
patient samples have been previously used in other studies.
AF cases were recruited from the Department of Medicine
I of the Ludwig-Maximilians-University Hospital Gros-
shadern, Munich. Detailed patient characteristics are listed
in Tables S1 and S2. Clinical parameters were available for
at least 95 % of all cases.
Control cohort
For follow-up genotyping of the SHOX2 c.*28T[C vari-
ant, we investigated 1576 unrelated long-lived individuals
with an age between 95 and 109 years who were recruited
from across Germany. A detailed description of the
sample and the recruitment procedure is reported else-
where [38]. A second control population consisted of 294
ethnically matched unrelated healthy individuals
(25–70 years), recruited from the Institute of Human
Genetics of the University Hospital Heidelberg. As heal-
thy controls for the miRNA measurement, we used plasma
samples from age-matched volunteers without history of
cardiac disease.
SHOX2 expression in human tissue samples
Human right atrial appendages (RAA) were collected
from patients undergoing cardiac surgery at the Depart-
ment for Cardiothoracic Surgery at Ludwig-Maximilians-
University Hospital Grosshadern, Munich. Seventeen
patients with AF and 17 patients with sinus rhythm and no
previous history of AF were recruited from 2014 to 2015.
After excision tissue was snap-frozen in liquid nitrogen
and stored at -80 C. Total RNA was isolated using
TRIzol. cDNA was synthesized using the SuperScript
First-Strand Synthesis System for RT-PCR (Invitrogen).
SHOX2 expression was measured by qPCR using TaqMan
probes for SHOX2 and GAPDH as a housekeeping gene
(Table S3). qPCR was performed using a CFX 96 C1000
touch Realtime Cycler (Bio Rad, Germany). Samples
were measured as triplicates.
Ethical statement
The study was approved by the local ethics committees and
was performed in accordance with the ethical standards
laid down in the 1964 Declaration of Helsinki and its later
amendments. All probands gave written informed consent
including consent to use DNA for genetic analyses prior to
their inclusion in the study.
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Sequencing and genotyping
PCR primers used to amplify each exon of SHOX2, the
flanking intron–exon boundaries and parts of the UTRs are
listed in Table S3. We analyzed the longest isoform of
SHOX2 including a primate specific exon 2 ?
(NM_003030). PCRs were performed with Paq5000 poly-
merase (from Stratagene) using standard conditions. The
PCR products were analyzed by gel electrophoresis. Ade-
quate amplification products were selected for purification
and sequencing done by GATC Biotech (GATC Biotech
AG, Konstanz, Germany).
Genotyping of the SHOX2 30UTR variant c.*28T[C in
long-lived individuals was performed with a Custom
TaqMan SNP Genotyping Assay (Life Technologies).
Generation of plasmid constructs
To introduce the c.242G[A/p.G81E and c.849C[A/
p.H283Q mutations into a previously described SHOX2
expression plasmid (human SHOX2 cDNA sub-cloned into
a pDEST27 vector, Invitrogen [24]) for luciferase reporter
assays, site-directed mutagenesis was performed using
mutated SHOX2 primers (Table S3). The zebrafish shox2
expression plasmid harbouring the p.H227Q (correspond-
ing to human p.H283Q) mutation was generated by site
directed mutagenesis of the previously described pDest-
Tol2CG2-shox2 plasmid [24] using specific primers
(Table S3). To generate luciferase reporter constructs, the
SHOX2 30UTR full-length wild type sequence (?1203/
?3222) was cloned into the psiCHECK-2 vector (Pro-
mega), while a part of the SHOX2 30UTR wild type
sequence (?1208/?2185) was cloned into the pRL-TK
vector (Promega), both downstream of a Renilla luciferase
reporter gene. Site-directed mutagenesis was performed to
introduce the c.*28C allele using mutated SHOX2 30UTR
primers (Table S3). Site-directed mutagenesis was per-
formed with the QuikChange II Site-Directed Mutagenesis
Kit (Agilent Technology) according to manufacture
instructions. All constructs were verified by sequencing.
Cell culture, transfection and luciferase assay
HEK293 cells were cultured at 37 C in DMEM medium
containing high glucose, supplemented with 10 % fetal calf
serum and antibiotics. HL-1 cells were cultured at 37 C in
Claycomb medium (Sigma-Aldrich), supplemented with
10 % fetal bovine serum, 2 mM L-glutamine, 100 lM
norepinephrine, 10U/ml penicillin and 100 lg/ml strepto-
mycin on flasks pre-coated with gelatine-fibronectin. For
luciferase assays, published SHOX2 targets BMP4 and ISL1
were used [24, 40]. HEK293 cells were co-transfected with
the respective pGL3-basic reporter constructs (1 lg)
together with SHOX2 wild type or mutant expression con-
structs (1 lg) using PEI. 24 h after transfection, luciferase
activity was determined and normalized to Renilla lucifer-
ase activity with a dual luciferase assay kit (Promega).
Experiments were performed independently at least
three times (each sample measured in triplicate in each
experiment) with consistent results.
For experimental validation of miRNA target sites using
a luciferase reporter system, HEK293 cells were trans-
fected with PEI and HL-1 cells were transfected with
Lipofectamine 2000 (Invitrogen) according to manufacture
instructions. Both cell lines were co-transfected with wild
type or mutant SHOX2 30UTR reporter constructs (200 ng)
together with mirVana miRNA mimics and/or miRVana
miRNA inhibitors at a final concentration of 5 nM. Dou-
ble-stranded RNA designed to mimic the endogenous
precursor hsa-miR-92b-5p as well as single-stranded RNA-
based oligonucleotides designed to specifically bind to and
inhibit miR-92b-5p and negative control miRNAs (Pre-miR
miRNA Precursor Negative Control #1 and miRVana
miRNA Inhibitor Negative Control #1), were purchased
from Ambion (Life Technologies). 48 h after transfection,
luciferase activity was determined and normalized to
Firefly luciferase activity with a dual luciferase assay kit
(Promega). Experiments were performed independently at
least three times (each sample measured in triplicate in
each experiment) with consistent results.
Zebrafish embryos and microinjections
Care and breeding of zebrafish, Danio rerio, were as descri-
bed previously [51]. For all plasmid andmorpholino injection
procedures, theTE4/6wild type strainwas used.Morpholino-
modified antisense oligonucleotides (MO; Gene Tools) were
directed against the splice donor site of shox2 intron 3,
causing the identical bradycardia phenotype as the shox2MO
directed against the translational start site. Both MOs have
been described previously [6, 24]. Shox2 antisense oligonu-
cleotides or a standard control oligonucleotide (MO control),
diluted in 0.2 mol/l KCl, were microinjected into one-cell-
stage zebrafish embryos [27]. For rescue experiments 0.32 ng
of pDestTol2CG2-shox2 or pDestTol2CG2-shox2H227Q
was microinjected into one-cell-stage embryos directly after
injection of 2.8 ng of shox2MO.
Animals and tissue samples
CD-1 wild type mice were obtained from Janvier. Right
atria of E11.5 hearts that comprise the Shox2 expressing
sinus venosus myocardium and venous valves and E11.5
total hearts were dissected. For total RNA isolation, TRIzol
was used according to manufacturer’s instructions
(Invitrogen).
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Human RNA samples
RNAs from human adult tissues were purchased from
Ambion Life Technologies (FirstChoice Human Total
RNA Survey Panel). The MRC-Wellcome Trust Human
Developmental Biology Resource (HDBR) in Newcastle,
England kindly provided RNAs from human fetal tissues.
Quantitative PCR (qPCR)
cDNA was synthesized using the SuperScript First-Strand
Synthesis System for RT-PCR (Invitrogen). For mRNA
measurements, Hypoxanthine phosphoribosyl transferase 1
(Hprt1/HPRT1) and Succinate dehydrogenase (Sdha/
SDHA) were used as housekeeping genes. MiRNA cDNA
was synthesized using the MystiCq microRNA cDNA
Synthesis Mix (Sigma-Aldrich). MystiCq microRNA
qPCR Assay System with miRNA qPCR assay primers
designed to target human and mouse miR-92b-5p, as well
as human and mouse positive control primers (SNORD44
human small nucleolar and RNU6-1 mouse small nuclear
RNAs, both ubiquitously expressed were used as house-
keeping genes for miRNA qPCR) in combination with a
MystiCq universal PCR primer were purchased from
Sigma-Aldrich. Primer sets used are presented in Table S3.
qPCR was performed on a 7500 Fast Real-Time PCR
System (Applied Biosystems) using SYBR Green ROX
dye (Thermo Scientific).
miRNA measurement in human plasma
Plasma collection
Blood of all subjects was collected via a direct venous
puncture into 9 ml EDTA tubes (Sarstedt Monovette). All
blood was processed for isolation of plasma within 4 h of
collection. Blood was processed by spinning at 4000 rpm
for 20 min at RT. Plasma was carefully transferred to a
fresh RNAse/DNAse free tube and stored at -80 C.
RNA isolation and miRNA measurement
RNA isolation and miRNA measurement was described in
detail previously [15]. In brief, total RNA was isolated
from 400 ml EDTA-plasma using the miRNeasy kit (Qia-
gen). As no housekeeping miRNA has been established and
validated to normalize for the miRNA content so far, we
chose to use a fixed volume of plasma per sample and a
synthetic Caenorhabditis elegans miR-39 (cel-miR-39, 20
fmol/sample, synthesized by Qiagen) as a spiked-in control
to normalize for individual RNA-isolation-related varia-
tions. 20fmol cel-miR-39 were introduced to each plasma
sample after addition of denaturating Qiazol solution. We
used a fixed volume of 5 ml diluted RNA for reverse
transcription using the TaqMan microRNA Reverse Tran-
scription kit (Applied Biosystems) according to the man-
ufacturer’s protocol. Subsequently, 1.33 ll of the product
was used to detect miRNA expression by quantitative PCR
using TaqMan qRT-PCR assays (Applied Biosystems).
Primer sets used are presented in Table S3. Quantitative
PCR reactions were performed on a Bio-Rad iQ5 system
using the following program: 10 min pre-incubation at
95 C, 40 cycles of 15 s denaturation at 95 C and 60 s of
elongation at 60 C. Values are normalized to cel-miR-39
and expressed as 2-[(CT microRNA)-(CT cel-miR-39)].
Statistical analysis
For the clinical characteristics analysis and miRNA mea-
surements in human plasma, data are presented as
mean ± SEM.An unpaired student’s t test was used for two-
group comparisons. Categorical variables were analyzed by
Fisher’s exact test. For the association study a Chi squared
(v2) test was used. A p value p\ 0.05 was considered sta-
tistically significant. For luciferase assays and zebrafish
injections, data are presented as mean ± SEM from at least
3-4 independent experiments. Comparisons between exper-
imental groupswere performedwithGraphPad Prism6using
paired t test or 1-way ANOVA. Differences were considered
significant if they showed a p-value of p\ 0.05.
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